Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Monday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other brokerages have also recently commented on AUTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Wells Fargo & Company lowered their target price on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, August 13th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.12.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $1.41 on Monday. The stock has a fifty day moving average price of $1.52 and a 200-day moving average price of $1.81. The company has a market cap of $375.26 million, a price-to-earnings ratio of -1.68 and a beta of 1.84. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $4.12.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. The business had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. Research analysts predict that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP increased its stake in shares of Autolus Therapeutics by 6.9% in the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock valued at $41,992,000 after buying an additional 1,746,020 shares during the period. Armistice Capital LLC increased its stake in shares of Autolus Therapeutics by 9.1% in the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock valued at $27,360,000 after buying an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd grew its holdings in Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after acquiring an additional 900,000 shares during the period. Atle Fund Management AB grew its holdings in Autolus Therapeutics by 5.8% during the 3rd quarter. Atle Fund Management AB now owns 1,169,634 shares of the company’s stock worth $1,907,000 after acquiring an additional 64,173 shares during the period. Finally, Bank of America Corp DE grew its holdings in Autolus Therapeutics by 2,891.7% during the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after acquiring an additional 942,540 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.